

Antonio D'Avolio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3027989/publications.pdf>

Version: 2024-02-01

314
papers

5,926
citations

87723

38
h-index

138251

58
g-index

317
all docs

317
docs citations

317
times ranked

7189
citing authors

#	ARTICLE	IF	CITATIONS
1	25-Hydroxyvitamin D Concentrations Are Lower in Patients with Positive PCR for SARS-CoV-2. <i>Nutrients</i> , 2020, 12, 1359.	1.7	337
2	Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. <i>Aids</i> , 2010, 24, 1064-1066.	1.0	120
3	A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 125, 369-375.	1.4	115
4	In vitro activity of propolis against <i>Streptococcus pyogenes</i> . <i>Letters in Applied Microbiology</i> , 2000, 31, 174-177.	1.0	112
5	An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 662-669.	1.0	105
6	New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 1721-1726.	1.2	98
7	Coronavirus disease 2019 and first-trimester spontaneous abortion: a case-control study of 225 pregnant patients. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 391.e1-391.e7.	0.7	94
8	Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2977-2980.	1.3	90
9	HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 859, 234-240.	1.2	80
10	Association of a Single Nucleotide Polymorphism in the Pregnane X Receptor (PXR) 63396C>T with Reduced Concentrations of Unboosted Atazanavir. <i>Clinical Infectious Diseases</i> , 2008, 47, 1222-1225.	2.9	77
11	Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study. <i>BMC Cancer</i> , 2014, 14, 184.	1.1	76
12	HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010, 52, 774-780.	1.4	71
13	Matrix effect management in liquid chromatography mass spectrometry: the internal standard normalized matrix effect. <i>Bioanalysis</i> , 2017, 9, 1093-1105.	0.6	69
14	Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1772-1777.	1.3	69
15	Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 396, 791-798.	1.9	68
16	LC-MS application for therapeutic drug monitoring in alternative matrices. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 166, 40-51.	1.4	67
17	Population Pharmacokinetic Modeling of the Association between 63396C>T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 5242-5250.	1.4	66
18	HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 59, 109-116.	1.4	66

#	ARTICLE	IF	CITATIONS
19	Nevirapine Plasma Exposure Affects both Durability of Viral Suppression and Selection of Nevirapine Primary Resistance Mutations in a Clinical Setting. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3966-3969.	1.4	65
20	Evaluation of the Mean Corpuscular Volume of Peripheral Blood Mononuclear Cells of HIV Patients by a Coulter Counter To Determine Intracellular Drug Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2976-2978.	1.4	64
21	Treatment Intensification Has no Effect on the HIV-1 Central Nervous System Infection in Patients on Suppressive Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 590-596.	0.9	62
22	Cannabinoids concentration variability in cannabis olive oil galenic preparations. <i>Journal of Pharmacy and Pharmacology</i> , 2017, 70, 143-149.	1.2	59
23	A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011, 54, 779-788.	1.4	58
24	Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 835, 127-130.	1.2	52
25	A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics?. <i>Current Drug Metabolism</i> , 2014, 15, 581-598.	0.7	52
26	The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 919-924.	1.3	51
27	Development, Validation, and Routine Application of a High-Performance Liquid Chromatography Method Coupled with a Single Mass Detector for Quantification of Itraconazole, Voriconazole, and Posaconazole in Human Plasma. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3408-3413.	1.4	51
28	Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-Infected Patients Are Associated With Compartmental Viral Control. <i>Clinical Infectious Diseases</i> , 2015, 60, 311-317.	2.9	50
29	Pharmacokinetics of linezolid during extracorporeal membrane oxygenation. <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 590-591.	1.1	43
30	Simultaneous Quantification of Linezolid, Rifampicin, Levofloxacin, and Moxifloxacin in Human Plasma Using High-Performance Liquid Chromatography With UV. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 104-109.	1.0	42
31	Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-Sectional Study of HIV-Positive Patients with Normal Renal Function. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1840-1843.	1.4	41
32	UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 138, 223-230.	1.4	41
33	Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B eAg negative and genotype D. <i>Liver International</i> , 2013, 33, 580-585.	1.9	40
34	Development and validation of a HPLC-UV method for the quantification of antiepileptic drugs in dried plasma spots. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 435-44.	1.4	40
35	Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 197-203.	1.1	40
36	Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC-MS. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2645-2649.	1.3	39

#	ARTICLE	IF	CITATIONS
37	UHPLC-MS/MS method with protein precipitation extraction for the simultaneous quantification of ten antihypertensive drugs in human plasma from resistant hypertensive patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 129, 535-541.	1.4	39
38	A New Assay Based on Solid-Phase Extraction Procedure with LC-MS to Measure Plasmatic Concentrations of Tenofovir and Emtricitabine in HIV Infected Patients. <i>Journal of Chromatographic Science</i> , 2008, 46, 524-528.	0.7	38
39	Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 759-765.	0.7	38
40	Colistin Use in Patients With Reduced Kidney Function. <i>American Journal of Kidney Diseases</i> , 2016, 68, 296-306.	2.1	38
41	Inosine Triphosphatase Polymorphisms and Ribavirin Pharmacokinetics as Determinants of Ribavirin-Associate Anemia in Patients Receiving Standard Anti-HCV Treatment. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 165-170.	1.0	37
42	Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 293-300.	0.7	37
43	Development and validation of an UPLC-PDA method to quantify daptomycin in human plasma and in dried plasma spots. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 88, 66-70.	1.4	37
44	Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 280-281.	1.3	36
45	Glycopeptide Bone Penetration in Patients with Septic Pseudoarthrosis of the Tibia. <i>Clinical Pharmacokinetics</i> , 2008, 47, 793-805.	1.6	36
46	Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3061-3066.	1.3	36
47	Drug Interactions between Warfarin and Efavirenz or Lopinavir-Ritonavir in Clinical Treatment. <i>Clinical Infectious Diseases</i> , 2008, 46, 146-147.	2.9	35
48	Development and validation of UHPLC-MS/MS methods for the quantification of colistin in plasma and dried plasma spots. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 129, 551-557.	1.4	35
49	Determinants of darunavir cerebrospinal fluid concentrations. <i>Aids</i> , 2012, 26, 1529-1533.	1.0	34
50	Sequential therapy with entecavir and PEG-IFN in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. <i>Journal of Viral Hepatitis</i> , 2013, 20, e11-9.	1.0	34
51	Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon. <i>Antiviral Research</i> , 2014, 102, 35-43.	1.9	34
52	Therapeutic drug monitoring-guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2535-2543.	1.1	34
53	Development and validation of a new UPLC-PDA method to quantify linezolid in plasma and in dried plasma spots. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 936, 42-47.	1.2	33
54	UHPLC-MS/MS method with sample dilution to test therapeutic adherence through quantification of ten antihypertensive drugs in urine samples. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 142, 279-285.	1.4	33

#	ARTICLE	IF	CITATIONS
55	Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBsAg negative with PEG-interferon. <i>Journal of Viral Hepatitis</i> , 2015, 22, 318-327.	1.0	32
56	Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 722-728.	1.0	31
57	UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 114, 127-132.	1.4	31
58	Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study. <i>Journal of Viral Hepatitis</i> , 2017, 24, 850-857.	1.0	31
59	Inpatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 232-235.	1.0	30
60	Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 134-140.	1.1	30
61	An UPLC-MS/MS method coupled with automated on-line SPE for quantification of tacrolimus in peripheral blood mononuclear cells. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 107, 512-517.	1.4	29
62	Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients. <i>Drugs</i> , 2016, 76, 1161-1174.	4.9	29
63	Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide. <i>Aids</i> , 2006, 20, 1977-1979.	1.0	28
64	Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy. <i>Emerging Infectious Diseases</i> , 2021, 27, 303-305.	2.0	28
65	Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. <i>Antiviral Research</i> , 2013, 100, 114-119.	1.9	27
66	High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 241-245.	1.3	27
67	Ceftriaxone bone penetration in patients with septic non-union of the tibia. <i>International Journal of Infectious Diseases</i> , 2011, 15, e415-e421.	1.5	26
68	Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 66, 376-380.	1.4	26
69	Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs. <i>Clinical Pharmacokinetics</i> , 2017, 56, 355-369.	1.6	26
70	Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. <i>Hepatology</i> , 2011, 54, 2279-2279.	3.6	25
71	A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2013, 78-79, 217-223.	1.4	25
72	Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir. <i>Journal of Viral Hepatitis</i> , 2014, 21, 260-263.	1.0	24

#	ARTICLE	IF	CITATIONS
73	Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines. <i>Pharmacogenomics Journal</i> , 2016, 16, 514-518.	0.9	24
74	<i>SLC22A2</i> variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1035-1043.	1.3	24
75	Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage. <i>Aids</i> , 2011, 25, 1437-1439.	1.0	23
76	UPLC-MS/MS method for quantification of the azathioprine metabolites 6-mercaptopguanosine and 6-methylmercaptapurine riboside in peripheral blood mononuclear cells. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 98, 271-278.	1.4	23
77	A LC-MS method to quantify tenofovir urinary concentrations in treated patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 114, 8-11.	1.4	23
78	A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2572-2575.	1.3	23
79	Pharmacogenetic of voriconazole antifungal agent in pediatric patients. <i>Pharmacogenomics</i> , 2018, 19, 913-925.	0.6	23
80	Virological Failure in HIV to Triple Therapy With Dolutegravir-Based Firstline Treatment: Rare but Possible. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofy332.	0.4	23
81	Daptomycin Plasma and CSF Levels in Patients with Healthcare-Associated Meningitis. <i>Neurocritical Care</i> , 2019, 31, 116-124.	1.2	23
82	A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 848, 374-378.	1.2	22
83	Tenofovir Coadministration Is Not Associated With Lower Unboosted Atazanavir Plasma Exposure in the Clinical Setting. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 431-432.	0.9	22
84	The E genotype of hepatitis B: Clinical and virological characteristics, and response to interferon. <i>Journal of Infection</i> , 2014, 69, 81-87.	1.7	22
85	Influence of single-nucleotide polymorphisms on deferasirox Ctrough levels and effectiveness. <i>Pharmacogenomics Journal</i> , 2015, 15, 263-271.	0.9	22
86	Efavirenz pharmacogenetics in a cohort of Italian patients. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 117-123.	1.1	22
87	LC-MS/MS-Based Quantification of 9 Antiepileptic Drugs From a Dried Sample Spot Device. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 331-339.	1.0	22
88	Measuring Intracellular Concentrations of Calcineurin Inhibitors: Expert Consensus from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Expert Panel. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 665-670.	1.0	22
89	Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 907-910.	1.3	21
90	Vitamin D pathway gene variants and HCV-2/3 therapy outcomes. <i>Antiviral Therapy</i> , 2014, 20, 335-341.	0.6	21

#	ARTICLE	IF	CITATIONS
91	Pharmacogenetics of ribavirin-induced anemia in HCV patients. <i>Pharmacogenomics</i> , 2016, 17, 925-941.	0.6	21
92	Serum Bactericidal Activity Levels Monitor to Guide Intravenous Dalbavancin Chronic Suppressive Therapy of Inoperable Staphylococcal Prosthetic Valve Endocarditis: A Case Report. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz427.	0.4	21
93	A Validated High-Performance Liquid Chromatography-Ultraviolet Method for Quantification of the CCR5 Inhibitor Maraviroc in Plasma of HIV-Infected Patients. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 86-92.	1.0	20
94	Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 90, 119-126.	1.4	20
95	First UHPLC-MS/MS method coupled with automated online SPE for quantification both of tacrolimus and everolimus in peripheral blood mononuclear cells and its application on samples from co-treated pediatric patients.. <i>Journal of Mass Spectrometry</i> , 2017, 52, 187-195.	0.7	20
96	A simple high performance liquid chromatography-mass spectrometry method for Therapeutic Drug Monitoring of isavuconazole and four other antifungal drugs in human plasma samples. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 145, 718-724.	1.4	20
97	Enhancement of calcyclin gene RNA expression in squamous cell carcinoma of the oral mucosa, but not in benign lesions. <i>Journal of Oral Pathology and Medicine</i> , 1997, 26, 206-210.	1.4	19
98	Posaconazole cerebrospinal concentrations in an HIV-infected patient with brain mucormycosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 224-225.	1.3	19
99	Cerebrospinal fluid penetration of tigecycline. <i>Scandinavian Journal of Infectious Diseases</i> , 2014, 46, 69-72.	1.5	19
100	Therapeutic drug monitoring of intracellular anti-infective agents. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 101, 183-193.	1.4	19
101	Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 409-411.	0.5	19
102	Anidulafungin for <i>Candida glabrata</i> Infective Endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4552-4553.	1.4	18
103	Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 826-827.	1.3	18
104	Development of Standard Operating Protocols for the Optimization of Cannabis-Based Formulations for Medical Purposes. <i>Frontiers in Pharmacology</i> , 2019, 10, 701.	1.6	18
105	Tipranavir (TPV) Genotypic Inhibitory Quotient Predicts Virological Response at 48 Weeks to TPV-Based Salvage Regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1066-1071.	1.4	17
106	Association of vitamin D pathway SNPs and clinical response to interferon in a cohort of HBeAg-negative patients. <i>Pharmacogenomics</i> , 2017, 18, 651-661.	0.6	17
107	Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017, 44, 1083-1088.	0.9	17
108	Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection. <i>Biomedicines</i> , 2017, 5, 66.	1.4	17

#	ARTICLE	IF	CITATIONS
109	Clinically Significant Drug Interaction between Tipranavir-Ritonavir and Phenobarbital in an HIV-Infected Subject. <i>Clinical Infectious Diseases</i> , 2007, 45, 1654-1655.	2.9	16
110	Telbivudine in the treatment of hepatitis B-associated cryoglobulinemia. <i>Journal of Clinical Virology</i> , 2013, 56, 167-169.	1.6	16
111	Ultra Performance Liquid Chromatography PDA Method for Determination of Tigecycline in Human Plasma. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 853-858.	1.0	16
112	Intracellular Antiviral Activity of Low-Dose Ritonavir in Boosted Protease Inhibitor Regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4042-4047.	1.4	16
113	How effective is the use of DBS and DPS as tools to encourage widespread therapeutic drug monitoring?. <i>Bioanalysis</i> , 2014, 6, 425-427.	0.6	16
114	UHPLC-MS/MS method with automated on-line solid phase extraction for the quantification of entecavir in peripheral blood mononuclear cells of HBV+ patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 118, 64-69.	1.4	16
115	Precision medicine for HIV: where are we?. <i>Pharmacogenomics</i> , 2018, 19, 145-165.	0.6	16
116	Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3655-e3664.	1.8	16
117	Marked increase in efavirenz and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis. <i>Malaria Journal</i> , 2011, 10, 141.	0.8	15
118	Dried plasma/blood spots for monitoring antiretroviral treatment efficacy and pharmacokinetics: a cross-sectional study in rural Burundi. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 801-808.	1.1	15
119	Role of pharmacogenetics on deferasirox AUC and efficacy. <i>Pharmacogenomics</i> , 2016, 17, 571-582.	0.6	15
120	Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 192-200.	1.3	14
121	Development and validation of an ultra performance liquid chromatography tandem mass method for sildenafil and N-desmethyl sildenafil plasma determination and quantification. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015, 1001, 35-40.	1.2	14
122	Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study). <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 3096-3099.	1.3	14
123	Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients. <i>Biomedicine and Pharmacotherapy</i> , 2015, 69, 47-55.	2.5	14
124	Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1741-1744.	1.3	14
125	Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. <i>Pharmacogenomics</i> , 2017, 18, 539-554.	0.6	14
126	A Common mdr1 Gene Polymorphism is Associated With Changes in Linezolid Clearance. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 602-609.	1.0	14

#	ARTICLE	IF	CITATIONS
127	The <i>hOCT1</i> and <i>ABCB1</i> polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 88021-88033.	0.8	14
128	A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1356-1364.	1.3	13
129	Raltegravir Penetration in Seminal Plasma of Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2744-2745.	1.4	13
130	Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg ϵ negative and genotype A, D and E. <i>Journal of Medical Virology</i> , 2014, 86, 1845-1850.	2.5	13
131	Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1911-1915.	1.3	13
132	ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy. <i>Biomedicine and Pharmacotherapy</i> , 2015, 69, 63-69.	2.5	13
133	Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics. <i>Pharmacogenomics</i> , 2017, 18, 865-880.	0.6	13
134	Serum Trimethylamine-N-oxide Concentrations in People Living with HIV and the Effect of Probiotic Supplementation. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105908.	1.1	13
135	An Improved HPLC Fluorimetric Method for the Determination of Enfuvirtide Plasma Levels in HIV-Infected Patients. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 110-115.	1.0	12
136	A Simple and Fast Method for Quantification of Ertapenem using Meropenem as Internal Standard in Human Plasma in a Clinical Setting. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 90-94.	1.0	12
137	Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naïve patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1686-1688.	1.3	12
138	Transplacental passage of etravirine and maraviroc in a multidrug-experienced HIV-infected woman failing on darunavir-based HAART in late pregnancy. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1938-1939.	1.3	12
139	Plasma and Intracellular Imatinib Concentrations in Patients With Chronic Myeloid Leukemia. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 410-412.	1.0	12
140	Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. <i>Antiviral Research</i> , 2014, 109, 7-14.	1.9	12
141	Pharmacokinetics of high dosage of linezolid in two morbidly obese patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2417-2418.	1.3	12
142	Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy. <i>Clinical Microbiology and Infection</i> , 2015, 21, 205.e1-205.e3.	2.8	12
143	Effective treatment of hepatitis C virus infection with sofosbuvir and daclatasvir 90 ϵ mg in a patient with severe epilepsy on oxcarbazepine. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 347-348.	1.1	12
144	Tenofovir clearance is reduced in HIV-positive patients with subclinical tubular impairment. <i>Aids</i> , 2016, 30, 915-920.	1.0	12

#	ARTICLE	IF	CITATIONS
145	Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 767-773.	1.1	12
146	Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients. <i>Medicina (Lithuania)</i> , 2019, 55, 441.	0.8	12
147	Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV. <i>Clinical Pharmacokinetics</i> , 2021, 60, 103-109.	1.6	12
148	Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 874-875.	1.3	11
149	Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients. <i>Aids</i> , 2010, 24, 931-932.	1.0	11
150	Pharmacokinetics of anidulafungin in two critically ill patients with septic shock undergoing CVWH. <i>Journal of Chemotherapy</i> , 2013, 25, 376-378.	0.7	11
151	VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 164-172.	0.7	11
152	Class-specific relative genetic contribution for key antiretroviral drugs. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 3074-3079.	1.3	11
153	UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 115, 443-449.	1.4	11
154	Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B. <i>Journal of Medical Virology</i> , 2016, 88, 1953-1959.	2.5	11
155	Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon. <i>Antiviral Research</i> , 2016, 136, 32-36.	1.9	11
156	Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors. <i>Infection</i> , 2017, 45, 103-106.	2.3	11
157	Effect of ABCG2 and ABCG2 Gene Polymorphisms and CSF to Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 1550-1556.	1.0	11
158	Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab. <i>Cancers</i> , 2019, 11, 125.	1.7	11
159	Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis. <i>Scientific Reports</i> , 2020, 10, 16178.	1.6	11
160	Therapeutic Drug Monitoring of Dalbavancin Treatment in Severe Necrotizing Fasciitis in 3 Critically Ill Patients: A Grand Round. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 165-168.	1.0	11
161	Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1113-1117.	1.3	10
162	Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 307-308.	1.3	10

#	ARTICLE	IF	CITATIONS
163	Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 657-661.	1.1	10
164	Vitamin D pathway gene polymorphisms as predictors of hepatitis C virus-related mixed cryoglobulinemia. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 307-310.	0.7	10
165	Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. <i>International Journal of Pharmaceutics</i> , 2016, 497, 287-292.	2.6	10
166	Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1659-1664.	1.3	10
167	Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 615-620.	1.1	10
168	Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes. <i>Pharmacogenomics Journal</i> , 2018, 18, 506-515.	0.9	10
169	Differential Dose Adjustments of Immunosuppressants after Resuming Boosted versus Unboosted HIV-Protease Inhibitors Postliver Transplant. <i>American Journal of Transplantation</i> , 2009, 9, 2429-2434.	2.6	9
170	Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1340-1345.	1.3	9
171	Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. <i>Antiviral Therapy</i> , 2011, 16, 499-504.	0.6	9
172	Pharmacokinetics of the raltegravir/maraviroc/etravirine combination. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1932-1934.	1.3	9
173	Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction. <i>Pharmacogenomics</i> , 2014, 15, 1281-1286.	0.6	9
174	Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms. <i>Antiviral Research</i> , 2014, 106, 105-110.	1.9	9
175	Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2015, 18, 171.	0.9	9
176	SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1155-1160.	1.3	9
177	Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1167-1176.	1.5	9
178	Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment. <i>Archives of Virology</i> , 2015, 160, 2009-2017.	0.9	9
179	Deferasirox AUC efficacy cutoff and role of pharmacogenetics. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1155-1157.	0.8	9
180	Deferasirox pharmacokinetic and toxicity correlation in β^2 -thalassaemia major treatment. <i>Journal of Pharmacy and Pharmacology</i> , 2016, 68, 1417-1421.	1.2	9

#	ARTICLE	IF	CITATIONS
181	Rhino-Orbital-Cerebral Mucormycosis after Allogeneic Hematopoietic Stem Cell Transplantation and Isavuconazole Therapeutic Drug Monitoring during Intestinal Graft versus Host Disease. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019061.	0.5	9
182	Cannabis-Based Oral Formulations for Medical Purposes: Preparation, Quality and Stability. <i>Pharmaceuticals</i> , 2021, 14, 171.	1.7	9
183	2002 SLC28A2 65C>T PREDICT SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS WITH HEPATITIS C TREATED WITH INTERFERON AND RIBAVIRIN, CONSIDERING ALL HCV GENOTYPE AND GENOTYPE 1/4. <i>Journal of Hepatology</i> , 2010, 52, S463.	1.8	8
184	Clinical and Virological Response to Entecavir in HBV-Related Chronic Hepatitis or Cirrhosis: Data from the Clinical Practice in a Single-Centre Cohort. <i>Antiviral Therapy</i> , 2013, 18, 87-94.	0.6	8
185	Estimating ribavirin plasma exposure: Genetics or therapeutic drug monitoring?. <i>Journal of Hepatology</i> , 2013, 59, 633-634.	1.8	8
186	A validated HPLC-MS method for quantification of the CCR5 inhibitor maraviroc in HIV+ human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 94, 65-70.	1.4	8
187	Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients. <i>Antiviral Research</i> , 2014, 108, 44-47.	1.9	8
188	Influence of ABCB11 and HNF4 β genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2846-2849.	1.3	8
189	Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma. <i>Journal of Pharmacy and Pharmacology</i> , 2017, 69, 1524-1530.	1.2	8
190	Pharmacokinetics of colistin methanesulfonate (CMS) in burn patients: Table 1. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 319-321.	1.3	8
191	Development and validation of an HPLC-UV method for quantification of elvitegravir and two other new antiretrovirals, dolutegravir and rilpivirine, in the plasma of HIV-positive patients. <i>Biomedical Chromatography</i> , 2018, 32, e4274.	0.8	8
192	Detection of stavudine concentrations in plasma of HIV-infected patients taking zidovudine. <i>Aids</i> , 2004, 18, 577-578.	1.0	7
193	Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 384-387.	1.3	7
194	Determination of telaprevir in plasma of HCV-infected patients by HPLC-UV. <i>IUBMB Life</i> , 2013, 65, 800-805.	1.5	7
195	Low-density lipoprotein and ritonavir: an interaction between antiretrovirals and lipids mediated by P-glycoprotein. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1760-1766.	1.3	7
196	Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 72, dkw492.	1.3	7
197	Darunavir-based Antiretroviral Therapy may Affect the Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in HCV/HIV-1 Coinfected Patients: Table 1. <i>Clinical Infectious Diseases</i> , 2016, 63, 285-286.	2.9	7
198	Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-naïve patients with chronic hepatitis B. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 324-327.	1.1	7

#	ARTICLE	IF	CITATIONS
199	Pharmacokinetics of meropenem in burn patients with infections caused by Gram-negative bacteria: Are we getting close to the right treatment?. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 20, 22-27.	0.9	7
200	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 628-639.	1.3	7
201	The impact of age on antiretroviral drug pharmacokinetics in the treatment of adults living with HIV. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 665-676.	1.5	7
202	Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4861-4867.	1.1	7
203	Trend of 25-hydroxycholesterol and 27-hydroxycholesterol plasma levels in patients affected by active chronic hepatitis B virus infection and inactive carriers. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2021, 210, 105854.	1.2	7
204	Efficacy, Tolerability and Virological Consequences of Long-Term Use of Unboosted Atazanavir Plus 2 NRTIs in HIV-Infected Patients. <i>Current HIV Research</i> , 2014, 12, 339-346.	0.2	7
205	Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV. <i>Pharmaceuticals</i> , 2021, 14, 12.	1.7	7
206	Prophylactic Drug Monitoring of Itraconazole in an Oncohematological Pediatric Patient Population. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 604-606.	1.0	6
207	Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study. <i>Infection</i> , 2012, 40, 69-75.	2.3	6
208	Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.6	6
209	Pharmacokinetics of linezolid in critically ill patients: impact of continuous venovenous haemofiltration. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 784-785.	1.1	6
210	Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3163-3166.	1.3	6
211	Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children. <i>Pharmacogenetics and Genomics</i> , 2018, 28, 17-22.	0.7	6
212	A simple UHPLC-PDA method with a fast dilute-and-shot sample preparation for the quantification of canrenone and its prodrug spironolactone in human urine samples. <i>Journal of Pharmacological and Toxicological Methods</i> , 2018, 94, 29-35.	0.3	6
213	Tenofovir disoproxil fumarate discontinuation for renal outcomes: any room for treatment personalization?. <i>Pharmacogenomics Journal</i> , 2019, 19, 65-71.	0.9	6
214	The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients. <i>Pharmacogenomics Journal</i> , 2019, 19, 417-427.	0.9	6
215	Data on the stability of darunavir/cobicistat suspension after tablet manipulation. <i>Data in Brief</i> , 2020, 30, 105552.	0.5	6
216	Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing. <i>Clinical Pharmacokinetics</i> , 2021, 60, 89-102.	1.6	6

#	ARTICLE	IF	CITATIONS
217	Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients. <i>Scientific Reports</i> , 2021, 11, 443.	1.6	6
218	Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context. <i>Biomedicines</i> , 2021, 9, 1288.	1.4	6
219	Role of IL28B genotype in the liver stiffness increase in untreated patients with chronic hepatitis C. <i>Infection, Genetics and Evolution</i> , 2017, 53, 195-198.	1.0	6
220	Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 885-889.	1.3	5
221	F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy. <i>Digestive and Liver Disease</i> , 2012, 44, S42.	0.4	5
222	Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1436-1439.	1.3	5
223	Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 545-549.	1.1	5
224	Treatment optimization of naïve HCV-1 patients using IL28B, RVR and fibrosis stage. <i>Antiviral Research</i> , 2015, 116, 45-47.	1.9	5
225	Deferasirox pharmacokinetic evaluation in β -thalassaemia paediatric patients. <i>Journal of Pharmacy and Pharmacology</i> , 2017, 69, 525-528.	1.2	5
226	Pharmacokinetics of first-line antitubercular drugs in plasma and PBMCs. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1146-1148.	1.1	5
227	A rapid and robust UHPLC-DAD method for the quantification of amphotericin B in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 138, 142-145.	1.4	5
228	Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens. <i>Archives of Virology</i> , 2018, 163, 961-967.	0.9	5
229	Determination of Perampanel in Dried Plasma Spots: Applicability to Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 309-314.	1.0	5
230	Effect of Gender and Age on Voriconazole Trough Concentrations in Italian Adult Patients. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2020, 45, 405-412.	0.6	5
231	Validation and Clinical Application of a New Liquid Chromatography Coupled to Mass Spectrometry (HPLC-MS) Method for Dalbavancin Quantification in Human Plasma. <i>Separations</i> , 2021, 8, 189.	1.1	5
232	A Non-Invasive Method for Detection of Antihypertensive Drugs in Biological Fluids: The Salivary Therapeutic Drug Monitoring. <i>Frontiers in Pharmacology</i> , 2021, 12, 755184.	1.6	5
233	A combined role for low vitamin D and low albumin circulating levels as strong predictors of worse outcome in COVID-19 patients. <i>Irish Journal of Medical Science</i> , 2023, 192, 423-430.	0.8	5
234	Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 482-484.	1.3	4

#	ARTICLE	IF	CITATIONS
235	Continuous intravenous infusion of enfuvirtide in a patient with a multidrug-resistant HIV strain. <i>International Journal of Clinical Pharmacy</i> , 2016, 38, 749-751.	1.0	4
236	Pharmacogenetic analysis of hepatitis C virus related mixed cryoglobulinemia. <i>Pharmacogenomics</i> , 2017, 18, 607-611.	0.6	4
237	The role of <scp>ITPA</scp> and ribavirin transporter genes polymorphisms in prediction of ribavirin-induced anaemia in chronic hepatitis C Egyptian patients. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017, 44, 965-968.	0.9	4
238	Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients. <i>Infection, Genetics and Evolution</i> , 2018, 60, 42-47.	1.0	4
239	Cerebrospinal fluid abacavir concentrations in <scp>HIV</scp>-positive patients following once-daily administration. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1380-1383.	1.1	4
240	Antiretroviral concentrations in the presence and absence of valproic acid. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1969-1971.	1.3	4
241	Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses?. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106297.	1.1	4
242	Medication burden and clustering in people living with HIV undergoing therapeutic drug monitoring. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4432-4438.	1.1	4
243	Analysis of Cannabinoids Concentration in Cannabis Oil Galenic Preparations: Harmonization between Three Laboratories in Northern Italy. <i>Pharmaceuticals</i> , 2021, 14, 462.	1.7	4
244	Monitoring Tacrolimus Concentrations in Whole Blood and Peripheral Blood Mononuclear Cells: Inter- and Intra-Patient Variability in a Cohort of Pediatric Patients. <i>Frontiers in Pharmacology</i> , 2021, 12, 750433.	1.6	4
245	Vitamin D-Related Genetics as Predictive Biomarker of Clinical Remission in Adalimumab-Treated Patients Affected by Crohn's Disease: A Pilot Study. <i>Pharmaceuticals</i> , 2021, 14, 1230.	1.7	4
246	Pharmacogenomic influence on sepsis outcome in critically ill patients. <i>Infezioni in Medicina</i> , 2017, 25, 45-49.	0.7	4
247	Is peritoneal fluid a sanctuary site for HIV?. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2052-2053.	1.3	3
248	Triple or dual therapy for HCV-1 naive patients? Optimizing selection tools. <i>Journal of Hepatology</i> , 2014, 61, 178-179.	1.8	3
249	Rilpivirine Pharmacokinetics in 3 HIV-Positive Patients With Liver Cirrhosis Concomitantly Receiving Pantoprazole. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 695-696.	1.0	3
250	Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β -thalassaemia. <i>Biomedicine and Pharmacotherapy</i> , 2016, 84, 1510-1512.	2.5	3
251	Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 621-623.	0.7	3
252	Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study. <i>Infection, Genetics and Evolution</i> , 2017, 51, 167-172.	1.0	3

#	ARTICLE	IF	CITATIONS
253	Correlation between Entecavir Penetration in Peripheral Blood Mononuclear Cells and HBV DNA Decay during Treatment of HBeAg-Negative Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2018, 23, 373-377.	0.6	3
254	Undetectable antimicrobial plasma concentrations in an HIV-positive patient with protein-losing enteropathy and chylothorax during Mycobacterium genavense and Leishmania abdominal infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 546-548.	1.3	3
255	Clinical relevance of deferasirox trough levels in β -thalassemia patients. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2018, 45, 213-216.	0.9	3
256	Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	3
257	Monoclonal antibodies with subnanomolar affinity to tenofovir for monitoring adherence to antiretroviral therapies: from hapten synthesis to prototype development. <i>Journal of Materials Chemistry B</i> , 2020, 8, 10439-10449.	2.9	3
258	Pharmacokinetics of bictegravir, emtricitabine and tenofovir alafenamide in a gastrectomized patient with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3320-3322.	1.3	3
259	Seasonal Variation of Antiretroviral Drug Exposure during the Year: The Experience of 10 Years of Therapeutic Drug Monitoring. <i>Biomedicines</i> , 2021, 9, 1202.	1.4	3
260	Lack of concordance between EMIT assay and LC-MS/MS for Therapeutic Drug Monitoring of Mycophenolic Acid: Potential increased risk for graft rejection?. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 187, 113337.	1.4	3
261	Anidulafungin versus fluconazole: clinical focus on IDSA and ESCMID guidelines. <i>Infezioni in Medicina</i> , 2014, 22, 107-11.	0.7	3
262	A probable drug-to-drug interaction between voriconazole and haloperidol in a CYP2C19 poor metabolizing patient. [corrected]. <i>Infezioni in Medicina</i> , 2015, 23, 367-9.	0.7	3
263	Calcyclin gene expression modulation by medroxyprogesterone acetate. <i>Biochemical Pharmacology</i> , 1997, 54, 299-305.	2.0	2
264	Ritonavir-dependent fluconazole boosting of nelfinavir: a report of three cases. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 483-485.	1.3	2
265	External Validation of the Bilirubin-Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients. <i>AAPS Journal</i> , 2013, 15, 308-315.	2.2	2
266	Comment on "Higher CNS Penetration-Effectiveness of Long-Term Combination Antiretroviral Therapy is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid". <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, e118-e119.	0.9	2
267	Pharmacokinetics of an antiretroviral regimen in a patient unable to swallow solid oral dosage forms. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 750-752.	0.5	2
268	Role of simeprevir plasma concentrations in HCV treated patients with dermatological manifestations. <i>Digestive and Liver Disease</i> , 2017, 49, 705-708.	0.4	2
269	Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients. <i>Pharmacogenetics and Genomics</i> , 2018, 28, 199-206.	0.7	2
270	Daclatasvir Plasma Levels in a Cohort of Patients with Hepatitis C Virus Infection Taking Methadone: A Prospective Analysis. <i>European Addiction Research</i> , 2018, 24, 184-188.	1.3	2

#	ARTICLE	IF	CITATIONS
271	Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate are not transported by Concentrative Nucleoside Transporter 2. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 94, 202-204.	0.8	2
272	Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients. <i>Data in Brief</i> , 2020, 33, 106445.	0.5	2
273	Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	1.4	2
274	Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human Plasma. <i>Pharmaceuticals</i> , 2021, 14, 460.	1.7	2
275	Sofosbuvirâ€based therapies in genotype 2 hepatitis C virus cirrhosis: A realâ€life experience with focus on ribavirin dose. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00811.	1.1	2
276	Vitamin D as Modulator of Drug Concentrations: A Study on Two Italian Cohorts of People Living with HIV Administered with Efavirenz. <i>Nutrients</i> , 2021, 13, 3571.	1.7	2
277	An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR). <i>Trials</i> , 2021, 22, 831.	0.7	2
278	Monthly Increase in Vitamin D Levels upon Supplementation with 2000 IU/Day in Healthy Volunteers: Result from â€Integriamociâ€, a Pilot Pharmacokinetic Study. <i>Molecules</i> , 2022, 27, 1042.	1.7	2
279	Ceftobiprole and daptomycin concentrations in valve tissue in a patient with mitralic native valve endocarditis. <i>Journal of Chemotherapy</i> , 2022, 34, 416-418.	0.7	2
280	L-HISTIDINE/MEDROXYPROGESTERONE ACETATE INTERACTION MODULATES HUMAN BREAST CANCER CELL GROWTH AND PROGESTIN RECEPTOR EXPRESSION IN VITRO. <i>Pharmacological Research</i> , 1997, 35, 119-122.	3.1	1
281	Does Iatrogenic Scleroderma due to Injection-Site Reaction to Enfuvirtide Impair Absorption of the Drug?. <i>Clinical Drug Investigation</i> , 2008, 28, 305-311.	1.1	1
282	Tuberculosis after gastrectomy, plasmatic concentration of antitubercular drugs. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2012, 4, e2012007.	0.5	1
283	Pharmacokinetics of caspofungin increased dosage in a patient on rifampin-containing anti-tubercular treatment. <i>Scandinavian Journal of Infectious Diseases</i> , 2013, 45, 882-884.	1.5	1
284	Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2586-2588.	1.3	1
285	No pharmacokinetic interaction between raltegravir and amlodipine. <i>Aids</i> , 2014, 28, 1993-1995.	1.0	1
286	The Role of IL28B Genotype in HCV-RNA Baseline Levels. <i>Intervirology</i> , 2016, 59, 67-68.	1.2	1
287	Sixty milligram daclatasvir is the right dose for hepatitis C virus treatment in combination with etravirine and darunavir/ritonavir. <i>Aids</i> , 2016, 30, 1491-1493.	1.0	1
288	Antihypertensive Bridge Therapy by Continuous Drug Infusion With an Elastomeric Pump in Device-Resistant Hypertension. <i>Hypertension</i> , 2016, 67, e3-4.	1.3	1

#	ARTICLE	IF	CITATIONS
289	Reasons to wait or to treat naive patients affected by chronic hepatitis C with low fibrosis stage and genotypes 2 or 3. <i>European Journal of Public Health</i> , 2017, 27, 938-941.	0.1	1
290	Vitamin D pathway gene polymorphisms affecting daclatasvir plasma concentration at 2 weeks and 1 month of therapy. <i>Pharmacogenomics</i> , 2018, 19, 701-707.	0.6	1
291	Novel "Matrix-Corrected Calibration" study for the detection of polyunsaturated fatty acids (PUFAs) in plasma and erythrocytes by means of a gas chromatography-mass spectrometry approach optimized to follow up long-term parental patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 176, 112764.	1.4	1
292	Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentration-Time Curve of Linezolid for Different ABCB1 Genotypes. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 254-255.	1.0	1
293	Analytical Validation and Clinical Application of Rapid Serological Tests for SARS-CoV-2 Suitable for Large-Scale Screening. <i>Diagnostics</i> , 2021, 11, 869.	1.3	1
294	Impact of imipenem concentration in lung perfusate and tissue biopsy during clinical ex-vivo lung perfusion of high-risk lung donors. <i>Minerva Anestesiologica</i> , 2020, 86, 617-626.	0.6	1
295	Single-Nucleotide Polymorphisms of ABCB1 Gene Influence Intracellular Concentrations of Dasatinib. <i>Blood</i> , 2012, 120, 4903-4903.	0.6	1
296	A description of Cannabinoid levels in Cannabis oil by high-performance liquid chromatography-mass spectrometry in a reference laboratory of North-Italy. <i>Phytomedicine</i> , 2022, 102, 154218.	2.3	1
297	P1373 Clinical significance of pharmacokinetics of ertapenem in an outpatient setting. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, S381.	1.1	0
298	P1385 Antibiotic diffusion in pseudoarthrosic infected bone: glycopeptides, uoroquinolones and carbapenems. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, S384-S385.	1.1	0
299	Steady-state Pharmacokinetic Comparison of Generic and Branded Formulations of Lamivudine, Stavudine, and Nevirapine in HIV-infected Ugandan Adults. <i>International Journal of Infectious Diseases</i> , 2008, 12, e199.	1.5	0
300	P1187 A CONCENTRATION-DEPENDENT PHARMACOKINETIC INTERACTION WITH TELAPREVIR INCREASES RIBAVIRIN CONCENTRATIONS AND LEADS TO HIGHER HAEMOGLOBIN DROP. <i>Journal of Hepatology</i> , 2014, 60, S482.	1.8	0
301	Quantification of tacrolimus in PBMCs samples in pediatric liver transplant patients and correlation with tacrolimus whole blood concentration. <i>Digestive and Liver Disease</i> , 2014, 46, e73.	0.4	0
302	Pharmacokinetic and pharmacogenetic analysis of tacrolimus in pediatric liver transplant patients in the early post-liver transplantation period. <i>Digestive and Liver Disease</i> , 2014, 46, e71.	0.4	0
303	Pharmacokinetics of high dosage of linezolid in two morbidly obese patients" authors' response: Figure 1.. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 3169-3169.	1.3	0
304	A Possible Role of Therapeutic Drug Monitoring in Virological Breakthrough during Simeprevir and PEG-IFN Treatment in HCV-4. <i>Intervirology</i> , 2016, 59, 283-284.	1.2	0
305	Sequential therapy with entecavir and peginterferon alpha in chronic hepatitis B: for many but not for all?. <i>Journal of Viral Hepatitis</i> , 2016, 23, 402-403.	1.0	0
306	Assessment of Anti-Hypertensive Drug Adherence by Serial Aldosterone-To-Renin Ratio Measurement. <i>Frontiers in Pharmacology</i> , 2021, 12, 668843.	1.6	0

#	ARTICLE	IF	CITATIONS
307	Combined Famd and ANOVA Investigation Leads to Significant Association Between the hOCT1/ABCB1 Diplotype and Both Efficacy and Tolerability in Patients Affected By Chronic Myeloid Leukemia. Blood, 2015, 126, 4838-4838.	0.6	0
308	The hOCT1 and ABCB1 Polymorphisms Don't Condition the Efficacy and Toxicity of Nilotinib As First-Line Treatment: An Italian Multicentric Experience. Blood, 2016, 128, 3951-3951.	0.6	0
309	Flecainide plasma level modifications during the ledipasvir/sofosbuvir coadministration in two patients affected by chronic hepatitis C. Antiviral Therapy, 2019, 24, 553-555.	0.6	0
310	A pharmacogenetic study in HIV-infected patients treated with ritonavir: hematological and cardiovascular disease risk analysis. Minerva Biotechnology and Biomolecular Research, 2022, 33, .	0.3	0
311	Physical and Chemical Stability of Urapidil in 0.9% Sodium Chloride in Elastomeric Infusion Pump. International Journal of Pharmaceutical Compounding, 2016, 20, 343-346.	0.0	0
312	Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in) Tj ETQq0 0 0 rgBT ₁ /Overlock 10 Tf 50 5	1.7	0
313	The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study. Antimicrobial Agents and Chemotherapy, 2022, , e0013622.	1.4	0
314	Antifungal Drug Plasma Exposures: A Possible Contribution of Vitamin D-Related Gene Variants. Pharmaceuticals, 2022, 15, 630.	1.7	0